Despite their potential, novel compounds face several challenges. Drug resistance is a significant issue, as cancer cells can adapt to evade the effects of treatment. Additionally, ensuring the selectivity and minimizing toxicity of these compounds are critical hurdles. The high cost and lengthy process of clinical trials also pose substantial barriers to the development of novel therapies.
